Uniunea Europeană - română - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatita, atopică - alte preparate dermatologice - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer manufacturing deutschland gmbh - germania - abrocitinibum - compr. film. - 100mg - preparate de uz dermatologic alte preparate de uz dermatologic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer manufacturing deutschland gmbh - germania - abrocitinibum - compr. film. - 200mg - preparate de uz dermatologic alte preparate de uz dermatologic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer manufacturing deutschland gmbh - germania - abrocitinibum - compr. film. - 50mg - preparate de uz dermatologic alte preparate de uz dermatologic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

fareva amboise - franta - fluconazolum - pulb. pt. susp. orala - 10mg/ml - antimicotice de uz sistemic derivati de triazol

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

fareva amboise - franta - fluconazolum - caps. - 150mg - antimicotice de uz sistemic derivati de triazol

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

fareva amboise - franta - fluconazolum - sol. perf. - 2mg/ml - antimicotice de uz sistemic derivati de triazol

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

fareva amboise - franta - fluconazolum - caps. - 50mg - antimicotice de uz sistemic derivati de triazol

Uniunea Europeană - română - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrita, reumatoida - imunosupresoare - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant poate fi utilizat ca monoterapie sau în asociere cu metotrexat. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Uniunea Europeană - română - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.